184 related articles for article (PubMed ID: 25784271)
21. Predictive values of urinary bladder tumor markers survivin and soluble-Fas comparison with cystoscopy and bladder tumor antigen.
Ganas V; Kalaitzis C; Sountoulides P; Giannakopoulos S; Touloupidis S
Minerva Urol Nefrol; 2012 Dec; 64(4):279-85. PubMed ID: 23288215
[TBL] [Abstract][Full Text] [Related]
22. Significance of positive urine cytology on progression and cancer-specific mortality of non--muscle-invasive bladder cancer.
Koga F; Kobayashi S; Fujii Y; Ishioka J; Yokoyama M; Nakanishi Y; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
Clin Genitourin Cancer; 2014 Jun; 12(3):e87-93. PubMed ID: 24169493
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of an orthotopic rat bladder urothelial cell carcinoma model by cystoscopy.
Hendricksen K; Molkenboer-Kuenen J; Oosterwijk E; Hulsbergen-van de Kaa CA; Witjes JA
BJU Int; 2008 Apr; 101(7):889-93. PubMed ID: 18201266
[TBL] [Abstract][Full Text] [Related]
24. Urine markers for bladder cancer surveillance: a systematic review.
Ratliff TL
J Urol; 2005 Nov; 174(5):2065-6. PubMed ID: 16217395
[No Abstract] [Full Text] [Related]
25. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
[TBL] [Abstract][Full Text] [Related]
26. [Aftercare of non-muscle invasive bladder cancer].
Schulz GB; Schlenker B; Stief CG
Urologe A; 2019 Aug; 58(8):943-952. PubMed ID: 31175377
[TBL] [Abstract][Full Text] [Related]
27. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer.
Todenhöfer T; Hennenlotter J; Guttenberg P; Mohrhardt S; Kuehs U; Esser M; Aufderklamm S; Bier S; Harland N; Rausch S; Gakis G; Stenzl A; Schwentner C
BMC Cancer; 2015 Mar; 15():155. PubMed ID: 25884545
[TBL] [Abstract][Full Text] [Related]
28. BTA TRAK urine test increases the efficacy of cytology in the diagnosis of low-grade transitional cell carcinoma of the bladder.
Gibanel R; Ribal MJ; Filella X; Ballesta AM; Molina R; Alcaraz A; Alcover JB
Anticancer Res; 2002; 22(2B):1157-60. PubMed ID: 12168917
[TBL] [Abstract][Full Text] [Related]
29. The efficiency of the EORTC scoring system for the prediction of recurrence and progression of non-muscle-invasive bladder cancer treated by bacillus Calmette-Guerin immunotherapy.
Ajili F; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Aug; 37(4):249-53. PubMed ID: 23899093
[TBL] [Abstract][Full Text] [Related]
30. Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review.
Wolfs JRE; Hermans TJN; Koldewijn EL; van de Kerkhof D
Urol Oncol; 2021 Mar; 39(3):161-170. PubMed ID: 33376063
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of bladder cancer in the elderly].
Fröhner M; Rübben H
Urologe A; 2015 Apr; 54(4):510-5. PubMed ID: 25794588
[TBL] [Abstract][Full Text] [Related]
32. Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial.
van der Aa MN; Steyerberg EW; Bangma C; van Rhijn BW; Zwarthoff EC; van der Kwast TH
J Urol; 2010 Jan; 183(1):76-80. PubMed ID: 19913254
[TBL] [Abstract][Full Text] [Related]
33. Are cystoscopy and urinary cytology sufficient to identify candidates for subsequent biopsy after bacillus Calmette-Guérin treatment in patients with bladder carcinoma in situ?
Haase RN; Harving N
Scand J Urol; 2015; 49(4):338-40. PubMed ID: 25660358
[No Abstract] [Full Text] [Related]
34. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder.
Rosen EM; Joseph A; Jin L; Yao Y; Chau MH; Fuchs A; Gomella L; Hastings H; Goldberg ID; Weiss GH
J Urol; 1997 Jan; 157(1):72-8. PubMed ID: 8976219
[TBL] [Abstract][Full Text] [Related]
35. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma.
Messer J; Shariat SF; Brien JC; Herman MP; Ng CK; Scherr DS; Scoll B; Uzzo RG; Wille M; Eggener SE; Steinberg G; Terrell JD; Lucas SM; Lotan Y; Boorjian SA; Raman JD
BJU Int; 2011 Sep; 108(5):701-5. PubMed ID: 21320275
[TBL] [Abstract][Full Text] [Related]
36. [Urinary cytology in cases of bladder cancer: a critical evaluation].
Rathert P
Urologe A; 2003 Jul; 42(7):908-11. PubMed ID: 12898033
[TBL] [Abstract][Full Text] [Related]
37. Thulium Laser Endoscopic En Bloc Enucleation of Nonmuscle-Invasive Bladder Cancer.
Migliari R; Buffardi A; Ghabin H
J Endourol; 2015 Nov; 29(11):1258-62. PubMed ID: 26102556
[TBL] [Abstract][Full Text] [Related]
38. [Follow-up of bladder cancer : The right examinations at the right time].
Olbert P; Goebell PJ; Hegele A
Urologe A; 2018 Jun; 57(6):693-701. PubMed ID: 29663062
[TBL] [Abstract][Full Text] [Related]
39. Retrospective study of various conservative treatment options with bacille Calmette-Guérin in bladder urothelial carcinoma T1G3: Maintenance therapy.
Palou-Redorta J; Solsona E; Angulo J; Fernández JM; Madero R; Unda M; Martínez-Piñeiro JA; Portillo J; Chantada V; Moyano JL
Actas Urol Esp; 2016; 40(6):370-7. PubMed ID: 26922518
[TBL] [Abstract][Full Text] [Related]
40. Role of NMP22 Bladder Check Test in early detection of bladder cancer with recurrence.
Kundal VK; Pandith AA; Hamid A; Shah A; Kundal R; Wani SM
Asian Pac J Cancer Prev; 2010; 11(5):1279-82. PubMed ID: 21198277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
